Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Lymphology ; 41(3): 103-10, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19013877

RESUMO

Identification of lymphatic vessels in normal tissue and vascular malformations has been considerably enhanced by the recently discovered lymphatic endothelial markers D2-40 and LYVE-1. However, comparative analysis of these two antibodies in the evaluation of lymphatic malformations has not been widely reported. We evaluated twenty lymphatic malformations of skin/subcutis/soft tissue with immunostaining for D2-40 and LYVE-1. Ten high-power fields from each section were scored for total number of immunopositive vessels using identical fields with both markers. Vessels were grouped by diameter (< 225 microm and > 225 microm), with each vessel categorized according to the percentage of its lumen showing immunopositivity (< 25, 26-75, or > 75). Endothelial staining intensity was graded low or high in each case. We found no significant difference between total number of vessels stained with D2-40 or LYVE-1 or between the 2 markers in terms of the percentage of luminal circumference stained or intensity in vessels smaller than 225 microm. LYVE-1 stained a higher percentage of luminal circumference of channels greater than 225 microm at both low and high intensities. Large channels stained much less and sometimes not at all with either antibody. D2-40 and LYVE-1 are both effective for highlighting endothelium of lymphatic malformations, staining similar percentages of channels. LYVE-1 provides more luminal staining in channels larger than 225 microm but is less specific also staining macrophages and adipocytes. Both markers are expressed less strongly or sometimes not at all in large channels.


Assuntos
Anticorpos Monoclonais , Biomarcadores/metabolismo , Sistema Linfático/anormalidades , Sistema Linfático/metabolismo , Proteínas de Transporte Vesicular/metabolismo , Adolescente , Anticorpos Monoclonais Murinos , Criança , Pré-Escolar , Endotélio/metabolismo , Feminino , Humanos , Imuno-Histoquímica , Lactente , Masculino , Sensibilidade e Especificidade , Proteínas de Transporte Vesicular/imunologia , Adulto Jovem
2.
CMAJ ; 164(6): 825-30, 2001 Mar 20.
Artigo em Inglês | MEDLINE | ID: mdl-11276552

RESUMO

We addressed the question of whether private health care is illegal in Canada by surveying the health insurance legislation of all 10 provinces. Our survey revealed multiple layers of regulation that seem to have as their primary objective preventing the public sector from subsidizing the private sector, as opposed to rendering privately funded practice illegal. Private insurance for medically necessary hospital and physician services is illegal in only 6 of the 10 provinces. Nonetheless, a significant private sector has not developed in any of the 4 provinces that do permit private insurance coverage. The absence of a significant private sector is probably best explained by the prohibitions on the subsidy of private practice by public plans, measures that prevent physicians from topping up their public sector incomes with private fees.


Assuntos
Programas Nacionais de Saúde/legislação & jurisprudência , Privatização/legislação & jurisprudência , Canadá , Financiamento Governamental/legislação & jurisprudência , Humanos , Prática Privada/legislação & jurisprudência , Mecanismo de Reembolso/legislação & jurisprudência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA